Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1600 publications
Persistence on dolutegravir-containing two- and three-drug-regimens in clinical practice.
Journal: International journal of STD & AIDS
Published: October 03, 2025
Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025.
Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Published: October 03, 2025
In vitro modulation of adipocyte differentiation by tenofovir alafenamide/disoproxil fumarate following challenge with recent ARV drugs.
Journal: Cell cycle (Georgetown, Tex.)
Published: September 30, 2025
Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/ emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study.
Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: September 30, 2025
Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis - United States, 2025.
Journal: MMWR. Morbidity and mortality weekly report
Published: September 18, 2025
Experience of treatment with long-acting injectable cabotegravir/rilpivirine (LA iCAB/RPV) in viremic young patients with perinatally acquired HIV with adherence challenges: a five-case series.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: September 03, 2025
Long-Acting Cabotegravir and Rilpivirine Treatment for HIV in Patients With Kidney Failure: Two Cases of Successful Transition to Long-Acting Injectable HIV Therapy.
Journal: Kidney medicine
Published: August 21, 2025
Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study.
Journal: The Pediatric infectious disease journal
Published: August 19, 2025
Minimal impact of pregnancy on rilpivirine pharmacokinetics in women living with HIV.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: August 19, 2025
Lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis.
Journal: The Medical letter on drugs and therapeutics
Published: August 12, 2025
Last Updated: 10/31/2025